These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
365 related articles for article (PubMed ID: 30797014)
1. The prognostic impact of primary tumour location in patients with stage II and stage III colon cancer receiving adjuvant therapy. A GISCAD analysis from three large randomised trials. Cascinu S; Poli D; Zaniboni A; Lonardi S; Labianca R; Sobrero A; Rosati G; Di Bartolomeo M; Scartozzi M; Zagonel V; Pella N; Banzi M; Torri V Eur J Cancer; 2019 Apr; 111():1-7. PubMed ID: 30797014 [TBL] [Abstract][Full Text] [Related]
2. Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status. Taieb J; Kourie HR; Emile JF; Le Malicot K; Balogoun R; Tabernero J; Mini E; Folprecht G; Van Laethem JL; Mulot C; Bouché O; Aparicio T; Michel P; Thaler J; Bridgewater J; Van Cutsem E; Perkins G; Lepage C; Salazar R; Laurent-Puig P; JAMA Oncol; 2018 Jul; 4(7):e173695. PubMed ID: 29167892 [TBL] [Abstract][Full Text] [Related]
3. The relationship between right-sided tumour location, tumour microenvironment, systemic inflammation, adjuvant therapy and survival in patients undergoing surgery for colon and rectal cancer. Patel M; McSorley ST; Park JH; Roxburgh CSD; Edwards J; Horgan PG; McMillan DC Br J Cancer; 2018 Mar; 118(5):705-712. PubMed ID: 29337962 [TBL] [Abstract][Full Text] [Related]
4. Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trials. Sinicrope FA; Chakrabarti S; Laurent-Puig P; Huebner L; Smyrk TC; Tabernero J; Mini E; Goldberg RM; Zaanan A; Folprecht G; Van Laethem JL; Le Malicot K; Shi Q; Alberts SR; Taieb J Eur J Cancer; 2021 Feb; 144():101-112. PubMed ID: 33341444 [TBL] [Abstract][Full Text] [Related]
5. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study. André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776 [TBL] [Abstract][Full Text] [Related]
6. Adjuvant chemotherapy for stage II right-sided and left-sided colon cancer: analysis of SEER-medicare data. Weiss JM; Schumacher J; Allen GO; Neuman H; Lange EO; Loconte NK; Greenberg CC; Smith MA Ann Surg Oncol; 2014 Jun; 21(6):1781-91. PubMed ID: 24643898 [TBL] [Abstract][Full Text] [Related]
7. Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial. Rosati G; Lonardi S; Galli F; Di Bartolomeo M; Ronzoni M; Zampino MG; Banzi M; Zaniboni A; Pasini F; Bozzarelli S; Garattini SK; Ferrari D; Montesarchio V; Mambrini A; Ciuffreda L; Galli F; Pusceddu V; Carlomagno C; Bidoli P; Amoroso D; Bochicchio AM; Frassineti L; Corsi D; Bilancia D; Pastorino A; De Stefano A; Labianca R; Eur J Cancer; 2021 May; 148():190-201. PubMed ID: 33744715 [TBL] [Abstract][Full Text] [Related]
8. Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials. Yothers G; Sargent DJ; Wolmark N; Goldberg RM; O'Connell MJ; Benedetti JK; Saltz LB; Dignam JJ; Blackstock AW; J Natl Cancer Inst; 2011 Oct; 103(20):1498-506. PubMed ID: 21997132 [TBL] [Abstract][Full Text] [Related]
9. Benefits and adverse events in younger versus older patients receiving adjuvant chemotherapy for colon cancer: findings from the Adjuvant Colon Cancer Endpoints data set. Hubbard J; Thomas DM; Yothers G; Green E; Blanke C; O'Connell MJ; Labianca R; Shi Q; Bleyer A; de Gramont A; Sargent D J Clin Oncol; 2012 Jul; 30(19):2334-9. PubMed ID: 22614981 [TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of primary tumor location in Stage III colorectal cancer-right-sided colon versus left-sided colon versus rectum: a nationwide multicenter retrospective study. Shida D; Inoue M; Tanabe T; Moritani K; Tsukamoto S; Yamauchi S; Sugihara K; Kanemitsu Y J Gastroenterol; 2020 Oct; 55(10):958-968. PubMed ID: 32651860 [TBL] [Abstract][Full Text] [Related]
11. Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy. Sinicrope FA; Foster NR; Yothers G; Benson A; Seitz JF; Labianca R; Goldberg RM; Degramont A; O'Connell MJ; Sargent DJ; Cancer; 2013 Apr; 119(8):1528-36. PubMed ID: 23310947 [TBL] [Abstract][Full Text] [Related]
12. Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials. Schmoll HJ; Twelves C; Sun W; O'Connell MJ; Cartwright T; McKenna E; Saif M; Lee S; Yothers G; Haller D Lancet Oncol; 2014 Dec; 15(13):1481-1492. PubMed ID: 25456367 [TBL] [Abstract][Full Text] [Related]
13. Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer. Kumar A; Kennecke HF; Renouf DJ; Lim HJ; Gill S; Woods R; Speers C; Cheung WY Cancer; 2015 Feb; 121(4):527-34. PubMed ID: 25332117 [TBL] [Abstract][Full Text] [Related]
14. Predictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancer. Zunder SM; van Pelt GW; Gelderblom HJ; Mancao C; Putter H; Tollenaar RA; Mesker WE Br J Cancer; 2018 Jul; 119(2):164-169. PubMed ID: 29755119 [TBL] [Abstract][Full Text] [Related]
15. Preoperative Serum Carcinoembryonic Antigen Level as a Prognostic Factor for Recurrence and Survival After Curative Resection Followed by Adjuvant Chemotherapy in Stage III Colon Cancer. Kim CG; Ahn JB; Jung M; Beom SH; Heo SJ; Kim JH; Kim YJ; Kim NK; Min BS; Koom WS; Kim H; Roh YH; Ma BG; Shin SJ Ann Surg Oncol; 2017 Jan; 24(1):227-235. PubMed ID: 27699609 [TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of primary tumour location after curative resection in Stage I-III colorectal cancer: a single-centre retrospective study. Inoue M; Kanemitsu Y; Tsukamoto S; Moritani K; Takamizawa Y; Daiko H Jpn J Clin Oncol; 2024 Jul; 54(7):753-760. PubMed ID: 38535894 [TBL] [Abstract][Full Text] [Related]
17. Effect of Adjuvant FOLFOX Chemotherapy Duration on Outcomes of Patients With Stage III Colon Cancer. Kumar A; Peixoto RD; Kennecke HF; Renouf DJ; Lim HJ; Gill S; Speers CH; Cheung WY Clin Colorectal Cancer; 2015 Dec; 14(4):262-8.e1. PubMed ID: 26123496 [TBL] [Abstract][Full Text] [Related]
18. Risk of recurrence in patients with colon cancer stage II and III: a systematic review and meta-analysis of recent literature. Böckelman C; Engelmann BE; Kaprio T; Hansen TF; Glimelius B Acta Oncol; 2015 Jan; 54(1):5-16. PubMed ID: 25430983 [TBL] [Abstract][Full Text] [Related]
19. Lower survival after right-sided versus left-sided colon cancers: Is an extended lymphadenectomy the answer? Lee L; Erkan A; Alhassan N; Kelly JJ; Nassif GJ; Albert MR; Rt Monson J Surg Oncol; 2018 Sep; 27(3):449-455. PubMed ID: 30217301 [TBL] [Abstract][Full Text] [Related]
20. Utilization and impact of adjuvant chemotherapy among patients with resected stage II colon cancer: a multi-institutional analysis. Ejaz A; Casadaban L; Maker AV J Surg Res; 2017 Jul; 215():12-20. PubMed ID: 28688636 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]